Skip to main content
2025 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Listen Now

Formulation and Delivery
Partner Presentation

Unlocking the Limit of Congruency: Copovidone ASD Innovation from Lab to Commercial Scale

Monday, November 10, 2025
12:30 PM - 1:30 PM CT
Location:360 Stage #4, Exhibit Hall

Sponsored By 
Formulation and Delivery Partner Presentation-Formulation

Description: Unlock the next phase of innovation in pharmaceutical formulation with this specialized session on copovidone-based amorphous solid dispersions (ASDs). Experts from BASF and Thermo Fisher Scientific will highlight the science and practical considerations behind maximizing drug loading while ensuring consistent dissolution performance and manufacturing robustness. Gain insights into how advanced analytics can uncover critical behavior at the limit of congruency (LoC) and guide smooth transitions from the lab to full-scale production. Through case studies, process optimization examples, and collaborative best practices, you will learn proven strategies to anticipate challenges, avoid development pitfalls, and accelerate your path to successful ASD commercialization.

Learning Objectives:

  • Understanding the Limit of Congruency (LoC) in copovidone-based ASDs : 1) Why does it matter for drug solubility and dissolution? 2) Risks of exceeding LoC during formulation development.
  • Understand how advanced Analytical Techniques can reveal subtle differences in amorphous/crystalline content and polymer-drug interactions. Explore case studies demonstrating the importance of advanced analytics for robust ASD development.
  • Apply CTC and Heckel analysis to evaluate and optimize tablet strength, compressibility, and manufacturability
  • Leveraging roller compaction and solid fraction adjustments for reliable commercial-scale tableting.